title: Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines.
abstract: BACKGROUND
  Oxaliplatin (L-OHP) is a platinum complex that possesses activity against human and murine cells in vitro and in vivo, including colorectal carcinoma-derived cell lines, and cells that have been selected for resistance to cisplatin. We report two consecutive phase II trials of L-OHP for treatment of patients with advanced colorectal carcinoma.
  
  
  METHODS
  Fifty-eight patients were entered in study I, and 51 patients in study II. All of the patients had tumor progression when they were treated, prior to their enrollment, with a fluoropyrimidine-containing regimen. In both trials treatment consisted of L-OHP, 130 mg/m2, by i.v. infusion for two hours; the treatment was repeated every 21 days.
  
  
  RESULTS
  Response to therapy: Study I: Fifty-five patients were assessed for response. The response rate was 11% (95% CI, 0.03-0.19). Study II: All 51 patients were assessed for response. The response rate was 10% (95% CI, 0.017-0.18). The overall response rate for the 106 evaluated patients was 10% (95% CI, 0.046-0.16). Times to disease progression in responders were 4, 4, 4.5+, 5, 5, 6, 6, 6, 6+, 9, and 13 months. The dose-limiting toxic effect was sensory peripheral neuropathy. The incidence of severe peripheral neuropathy grades was: Study I: grade 3, 23% of patients, and grade 4, 8% of patients. Severe neuropathy had a favorable course in all of the patients who had long-term neurologic follow-up. Diarrhea and myeloid impairment were minor.
  
  
  CONCLUSIONS
  L-OHP produced modest, but definite antitumor activity in patients with advanced colorectal carcinoma who were previously resistant to chemotherapy including fluoropyrimidines. Toxicity is within acceptable limits of tolerance at the dose and schedule of oxaliplatin used in this trial.
authors.affiliation: Department of Hematology and Oncology, Hospital Paul Brousse, Villejuif, France.
authors.forename: D
authors.initials: D
authors.lastname: Machover
authors.forename: E
authors.initials: E
authors.lastname: Diaz-Rubio
authors.forename: A
authors.initials: A
authors.lastname: de Gramont
authors.forename: A
authors.initials: A
authors.lastname: Schilf
authors.forename: J J
authors.initials: JJ
authors.lastname: Gastiaburu
authors.forename: S
authors.initials: S
authors.lastname: Brienza
authors.forename: M
authors.initials: M
authors.lastname: Itzhaki
authors.forename: G
authors.initials: G
authors.lastname: Metzger
authors.forename: D
authors.initials: D
authors.lastname: N'Daw
authors.forename: J
authors.initials: J
authors.lastname: Vignoud
authors.forename: A
authors.initials: A
authors.lastname: Abad
authors.forename: E
authors.initials: E
authors.lastname: Francois
authors.forename: E
authors.initials: E
authors.lastname: Gamelin
authors.forename: M
authors.initials: M
authors.lastname: Marty
authors.forename: J
authors.initials: J
authors.lastname: Sastre
authors.forename: J F
authors.initials: JF
authors.lastname: Seitz
authors.forename: M
authors.initials: M
authors.lastname: Ychou
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D015179:Colorectal Neoplasms / Q000188:drug therapy*; D019008:Drug Resistance, Neoplasm; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D000077150:Oxaliplatin; D011743:Pyrimidines / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; D011743:Pyrimidines; D000077150:Oxaliplatin